ReEngage Therapeutics Inc. Press Releases

• Published on February 11, 2025 - 13:00 GMT

  

  ReEngage Therapeutics Joins Texas Medical Center’s 2025 Accelerator for Cancer Therapeutics

  ReEngage is one of twenty-four entities chosen through a selective process to be immersed in the nine-month program funded by CPRIT HOUSTON, TX, UNITED STATES, February 11, 2025 /⁨EINPresswire.com⁩/ -- ReEngage Therapeutics, a biotech company pioneering …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on July 9, 2024 - 13:00 GMT

  

  ReEngage Therapeutics Announces Research Agreement to Accelerate Development of ACSS2 Inhibitors as Cancer Therapies

  ReEngage partners with globally-recognized cancer center to study ACSS2 and its role in acetate metabolism, histone modification and DNA Damage Response HOUSTON, TX, USA, July 9, 2024 /⁨EINPresswire.com⁩/ -- ReEngage Therapeutics, a biotech company …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on May 21, 2024 - 13:00 GMT

  

  ReEngage Therapeutics Launches to Develop ACSS2 Inhibitor Compounds for Cancer Indications

  Expands therapeutic reach of novel class with potential in established oncology data HOUSTON, TEXAS, UNITED STATES, May 21, 2024 /⁨EINPresswire.com⁩/ -- ReEngage Therapeutics, a biotech company pioneering epigenetics to treat longevity-related diseases, …

  Distribution channels: Healthcare & Pharmaceuticals Industry ...